RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A C SterneNIHR Bristol Biomedical Research Centre, Bristol, UKJelena SavovićNIHR CLAHRC West, University Hospitals Bristol NHS Foundation Trust, Bristol, UKMatthew J. PageSchool of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaRoy G. ElbersPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UKNatalie BlencoweNIHR Bristol Biomedical Research Centre, Bristol, UKIsabelle BoutronCochrane France, Paris, FranceChristopher J CatesPopulation Health Research Institute, St George's, University of London, London, UKHung‐Yuan ChengNIHR Bristol Biomedical Research Centre, Bristol, UKMark CorbettCentre for Reviews and Dissemination, University of York, York, UKSandra EldridgePragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary University of London, UKJonathan EmbersonMRC Population Heath Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UKMiguel A. HernánDepartments of Epidemiology and Biostatistics, Harvard T H Chan School of Public Health, Harvard-MIT Division of Health Sciences of Technology, Boston, MA, USASally HopewellCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UKAsbjørn HróbjartssonCentre for Evidence-Based Medicine Odense, Odense University Hospital, Odense, DenmarkDaniela R. JunqueiraDepartment of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, CanadaPeter JüniApplied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, CanadaJamie J KirkhamCentre for Biostatistics, University of Manchester, Manchester, UKToby J LassersonEditorial and Methods Department, Cochrane Central Executive, London, UKTianjing LiDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAAlexandra McAleenanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UKBarnaby C ReevesNIHR Bristol Biomedical Research Centre, Bristol, UKSasha ShepperdNuffield Department of Population Health, University of Oxford, Oxford, UKIan ShrierCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, CanadaLesley StewartCentre for Reviews and Dissemination, University of York, York, UKKate TillingMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UKIan R. WhiteMRC Clinical Trials Unit, University College London, London, UKPenny WhitingNIHR CLAHRC West, University Hospitals Bristol NHS Foundation Trust, Bristol, UKJulian P. T. HigginsNIHR Bristol Biomedical Research Centre, Bristol, UK
2019en
ABI
Аннотация
Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 10Использованных источников: 0